Viad Competitors

HMS (NASDAQ:HMSY) and Viad (NYSE:VVI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for HMS and Viad, as reported by MarketBeat.

HMS currently has a consensus target price of $34.25, suggesting a potential downside of 7.37%. Given HMS's higher probable upside, equities analysts clearly believe HMS is more favorable than Viad.

Earnings and Valuation

This table compares HMS and Viad's top-line revenue, earnings per share and valuation.

HMS has higher earnings, but lower revenue than Viad. Viad is trading at a lower price-to-earnings ratio than HMS, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HMS and Viad's net margins, return on equity and return on assets.

Insider & Institutional Ownership

95.8% of HMS shares are owned by institutional investors. Comparatively, 88.3% of Viad shares are owned by institutional investors. 2.7% of HMS shares are owned by insiders. Comparatively, 1.7% of Viad shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

HMS has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Viad has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Summary

HMS beats Viad on 10 of the 13 factors compared between the two stocks.

ExlService (NASDAQ:EXLS) and Viad (NYSE:VVI) are both business services companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Profitability

This table compares ExlService and Viad's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ExlService and Viad's top-line revenue, earnings per share and valuation.

ExlService has higher earnings, but lower revenue than Viad. Viad is trading at a lower price-to-earnings ratio than ExlService, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

94.8% of ExlService shares are owned by institutional investors. Comparatively, 88.3% of Viad shares are owned by institutional investors. 3.6% of ExlService shares are owned by insiders. Comparatively, 1.7% of Viad shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

ExlService has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Viad has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for ExlService and Viad, as reported by MarketBeat.

ExlService currently has a consensus target price of $73.40, suggesting a potential downside of 20.91%. Given ExlService's higher probable upside, equities analysts clearly believe ExlService is more favorable than Viad.

Summary

ExlService beats Viad on 10 of the 13 factors compared between the two stocks.

Accolade (NASDAQ:ACCD) and Viad (NYSE:VVI) are both business services companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current recommendations and price targets for Accolade and Viad, as provided by MarketBeat.com.

Accolade presently has a consensus price target of $54.6364, suggesting a potential upside of 15.80%. Given Accolade's higher probable upside, research analysts clearly believe Accolade is more favorable than Viad.

Earnings & Valuation

This table compares Accolade and Viad's top-line revenue, earnings per share and valuation.

Viad has higher revenue and earnings than Accolade.

Profitability

This table compares Accolade and Viad's net margins, return on equity and return on assets.

Insider & Institutional Ownership

34.7% of Accolade shares are owned by institutional investors. Comparatively, 88.3% of Viad shares are owned by institutional investors. 1.7% of Viad shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Accolade beats Viad on 5 of the 8 factors compared between the two stocks.

Phreesia (NYSE:PHR) and Viad (NYSE:VVI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Volatility and Risk

Phreesia has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Viad has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Phreesia and Viad, as provided by MarketBeat.com.

Phreesia currently has a consensus target price of $53.6429, suggesting a potential upside of 1.44%. Given Phreesia's higher possible upside, research analysts clearly believe Phreesia is more favorable than Viad.

Earnings & Valuation

This table compares Phreesia and Viad's gross revenue, earnings per share (EPS) and valuation.

Viad has higher revenue and earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than Viad, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Phreesia and Viad's net margins, return on equity and return on assets.

Insider and Institutional Ownership

75.4% of Phreesia shares are owned by institutional investors. Comparatively, 88.3% of Viad shares are owned by institutional investors. 28.2% of Phreesia shares are owned by insiders. Comparatively, 1.7% of Viad shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Viad beats Phreesia on 8 of the 13 factors compared between the two stocks.

EVO Payments (NASDAQ:EVOP) and Viad (NYSE:VVI) are both business services companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, valuation and risk.

Volatility and Risk

EVO Payments has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Viad has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Earnings & Valuation

This table compares EVO Payments and Viad's gross revenue, earnings per share (EPS) and valuation.

Viad has higher revenue and earnings than EVO Payments. Viad is trading at a lower price-to-earnings ratio than EVO Payments, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for EVO Payments and Viad, as provided by MarketBeat.com.

EVO Payments currently has a consensus target price of $27.2857, suggesting a potential downside of 3.82%. Given EVO Payments' higher possible upside, research analysts clearly believe EVO Payments is more favorable than Viad.

Profitability

This table compares EVO Payments and Viad's net margins, return on equity and return on assets.

Insider and Institutional Ownership

52.7% of EVO Payments shares are owned by institutional investors. Comparatively, 88.3% of Viad shares are owned by institutional investors. 51.0% of EVO Payments shares are owned by insiders. Comparatively, 1.7% of Viad shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

EVO Payments beats Viad on 8 of the 13 factors compared between the two stocks.

NIC (NASDAQ:EGOV) and Viad (NYSE:VVI) are both computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Risk & Volatility

NIC has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Viad has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Insider & Institutional Ownership

89.7% of NIC shares are held by institutional investors. Comparatively, 88.3% of Viad shares are held by institutional investors. 2.7% of NIC shares are held by company insiders. Comparatively, 1.7% of Viad shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares NIC and Viad's revenue, earnings per share (EPS) and valuation.

NIC has higher earnings, but lower revenue than Viad. Viad is trading at a lower price-to-earnings ratio than NIC, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NIC and Viad's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for NIC and Viad, as provided by MarketBeat.

NIC currently has a consensus target price of $30.50, suggesting a potential downside of 10.24%. Given NIC's higher possible upside, equities analysts clearly believe NIC is more favorable than Viad.

Summary

NIC beats Viad on 10 of the 13 factors compared between the two stocks.